Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 23c

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q2 EPS of ($0.52), $0.23 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.

You May Also Be Interested In

• Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
• CrowdStrike Holdings Inc. (CRWD) call put ratio 2.2 calls to 1 put into quarter results
• UBS Reiterates Neutral Rating on Green Plains Renewable Energy (GPRE)